Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Cadila Pharmaceuticals Launches Joint Venture With Novavax in India

By Pharmaceutical Processing | July 9, 2009

Novavax, Inc. and Cadila Pharmaceuticals have announced the launch of their jointventure in India under the agreement signed between the two companies in March2009. This joint venture, called CPL Biologicals Pvt. Ltd., will develop andmanufacture vaccines, biological therapeutics and diagnostics in India usingtechnology contributed from Novavax and Cadila Pharmaceuticals. In addition,CPL Biologicals will establish manufacturing facilities in India and develop,produce and sell products such as seasonal influenza vaccine and potentiallyother novel vaccines against dengue fever and chikungunya fever based onNovavax’s virus-like-particle (VLP) vaccine technology. CPL Biologicals alsoexpects to develop the pandemic H1N1 influenza vaccine candidate in India thatNovavax is developing in the United States. Mr. I. A. Modi, Chairman of CPL Biologicals, noted: “This joint venturerepresents an important strategic alliance for vaccine development andmanufacturing in India and uses unique and cutting-edge vaccine technology.Our vision is to be a leading provider of high quality, affordable vaccines,biological therapeutics and diagnostics through world-class research andinnovative manufacturing to address current and future global healthchallenges.” Rahul Singhvi, President and Chief Executive Officer of Novavax, stated:”We are excited to see the agreement with Cadila announced in March come tofruition with the official launch of CPL Biologicals today. We look forwardto a long and successful effort to bring important new vaccines and otherpharmaceutical products to the people of India.”

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards